Methotrexate (hydrate) – 50 mg

Brand:
Cayman
CAS:
133073-73-1
Storage:
-20
UN-No:
De Minimis - 1544 / 6.1

Methotrexate (MTX) is similar in structure to folic acid (Item No. 20515) and aminopterin (Item No. 21802). It acts by inhibiting the metabolism of folic acid and blocking key enzymes in the synthesis of purines and pyrimidines required for cell proliferation.{21827,21826} MTX is known to induce adenosine release, which mediates many of its anti-inflammatory effects, including the reduction of proinflammatory cytokines.{21826,21828,21830} Formulations containing MTX have been used in the treatment of cancer, autoimmune diseases, ectopic pregnancy, and for the induction of medical abortions.{21829,7669} MTX formulations have been considered the gold standard of disease-modifying antirheumatic drug (DMARD) therapy to treat both the immune-inflammatory and joint destructive processes of rheumatoid arthritis.{11121}  

 

SKU: - Category:

Description

A folic acid and aminopterin derivative; inhibits folic acid metabolism; inhibits purine and pyrimidine synthesis, blocking cell proliferation; induces adenosine release; has anti-inflammatory effects; has been considered the gold standard of DMARD therapy for the immune-inflammatory and joint destructive processes of rheumatoid arthritis


Formal name: N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid, hydrate

Synonyms:  Amethopterin|CL 14,377|EMT 25299|MTX|NSC 740|R 9985

Molecular weight: 454.4

CAS: 133073-73-1

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Nucleic Acid Turnover/Signaling||Research Area|Cancer||Research Area|Immunology & Inflammation|Autoimmunity|Rheumatoid Arthritis